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Susceptibility testing and resistance phenotype 
detection in Staphylococcus aureus strains 
isolated from patients with atopic dermatitis, 
with apparent and recurrent skin colonization
Staphylococcus aureus resistance to antibiotics is on the increase. 
As exacerbating atopic dermatitis by S. aureus is well recognized 
Ke˛dzierska et al. have studied resistance patterns to a variety 
of antibiotics. Patients had a significantly higher prevalence of 
chloramphenicol-resistant S. aureus than healthy nasal carriers 
(P < 0.01). Similar rates of resistance were expressed to tetracycline, 
erythromycin, mupirocin, clindamycin and penicillin. Nearly 35% 
of S. aureus strains from lesional skin demonstrated a different anti-
microbial sensitivity pattern compared with strains colonizing non-
lesional skin of the same patient. The trend of increasing resistance 
to chloramphenicol, erythromycin and fusidic acid was observed 
among S. aureus recovered from patients after approximately 75 
days of treatment. Br J Dermatol 2008; 159:1290–9.
The Ludwig pattern of androgenetic alopecia 
is due to a hierarchy of androgen sensitivity 
within follicular units that leads to selective 
miniaturization and a reduction in the number 
of terminal hairs per follicular unit
Yazdabadi et al. hypothesized that there is an additional layer to 
the patterning in androgenetic alopecia (AA), with a hierarchy of 
susceptibility within follicular units (FUs) to AA, and that the dif-
fuse hair loss seen in women with AA is due to a reduction in the 
number of terminal hairs per FU rather than uniform miniaturiza-
tion of entire FUs. They compared the mean numbers of FUs and 
terminal hairs per FU in 4-mm scalp punch biopsies in 24 women 
with AA with those in 21 controls. There was no significant differ-
ence in the number of FUs; however, women with AA had 2.40 
terminal hairs per FU compared with 3.38 in the control group 
(P = 0.0001) associated with a mean increase of 0.6 vellus hairs 
per FU. Complete miniaturization of all hairs within the FU was 
not seen. Diffuse hair loss in women with AA is due to a reduction 
in the number of terminal hairs per FU and an increase in the num-
ber of vellus hairs. This supports the hypothesis of a hierarchy of 
susceptibility within FUs to AA. Br J Dermatol 2008; 159:1300–2.
Superficial acral fibromyxoma: a clinico ­
pathological study of new 41 cases from the 
U.K.: should myxoma (NOS) and fibroma (NOS) 
continue as part of 21st century reporting?
Prescott et al. studied 41 cases of superficial acral fibromyxoma 
(SAF) and document the U.K. experience with this new entity. 
The patients comprised 27 men and 14 women, age range 19–91 
years (mean 50, median 47) presenting with a solitary mass or 
nodule with a mean size of 1.92 cm. The common clinical sites 
were the toes (n = 29) and fingers (n = 11) as well as the palm 
(n = 1), with more than 75% of cases close to or involving the nail 
bed. Histologically, all cases presented as proliferation of spindle-
shaped and ⁄or stellate cells with a storiform and fasci cular pattern 
embedded in a fibromyxoid ⁄collagenous stroma with conspicuous 
mast cells. Multinucleated cells were observed (n = 22), increased 
number of blood vessels in the stroma and extravasation of red 
blood cells (n = 4). The characteristic immunophenotype was 
CD34+, CD99+ ⁄–, epithelial membrane antigen+ focally⁄–, S100–, 
desmin–, smooth muscle actin–, HMB45– and cytokeratin–. SAF is 
a distinct entity with typical clinical, histological and immunohis-
tochemical features. Complete excision and follow-up review are 
recommended. Br J Dermatol 2008; 159:1315–21.
Psoriasis and the risk of incident diabetes 
mellitus: a population­based study
Using the U.K.-based General Practice Research Database Brauchli 
et al. assessed and compared incidence rates of new-onset diabetes 
mellitus (DM) between patients with psoriasis and nonpsoriatic 
controls, and explored the role of psoriasis severity and body mass 
index (BMI). Within the study population of 65 448 patients they 
identified 1061 incident cases of DM. Of these, 59% had a history 
of psoriasis, yielding a crude incidence rate ratio of 1.36 (95% CI 
1.20–1.53). The adjusted odds ratio (OR) for patients with ≥ 2 years 
disease duration and > 2 prescriptions per year for oral psoriasis 
treatment was 2.56 (95% CI 1.11–5.92). In an analysis restricted 
to patients with normal BMI, the adjusted OR was 2.02 (95% CI 
1.31–3.10). In this large observational study the risk of incident 
DM was increased for patients with psoriasis as compared with a 
psoriasis-free comparison group. The risk increased with psoria-
sis duration and severity and was not driven by high BMI alone. 
Br J Dermatol 2008; 159:1331–7.
Polymorphic light eruption and skin cancer 
prevalence: is one protective against the other?
As there is increased immune surveillance and resistance to immune 
suppression following ultraviolet radiation (UVR) exposure in poly-
morphic light eruption (PLE) one might expect a protective effect 
of PLE against skin cancer and conversely a reduced risk of PLE 
among patients with skin cancer. Lembo et al. constructed a pro-
spective case–control study to see if this were the case. Two groups 
were studied: a group comprising 214 patients with skin cancer 
and 210 gender- and aged-matched controls, and a group com-
prising 100 patients with PLE and 155 gender- and aged-matched 
controls. Each participant answered a questionnaire aimed at estab-
lishing personal and family history of skin cancer and photoderma-
toses. Skin type and exposure to UVR were also documented. The 
prevalence of PLE in people with skin cancer was 7.5%, compared 
with 21.4% for controls (P < 0.001). The prevalence of skin can-
cer in patients with PLE was 4% compared with 7.1% for controls. 
There is strong evidence of reduced prevalence of PLE in patients 
with skin cancer and a trend for reduced incidence of skin cancer 
in patients with PLE. Br J Dermatol 2008; 159:1342–7.
